InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design (vol 11, pg 1017, 2020)

被引：2
|
作者：
Battelino, Tadej [1 ]
Bosnyak, Zsolt [2 ]
Danne, Thomas [3 ]
Mukherjee, Bhaswati [2 ]
Edelman, Steve [4 ]
Pilorget, Valerie [2 ]
Choudhary, Pratik [5 ,6 ]
Renard, Eric [7 ,8 ,9 ]
Bergenstal, Richard [10 ]
机构：
[1] Univ Ljubljana, Fac Med, Univ Childrens Hosp, UMC, Ljubljana, Slovenia
[2] Sanofi SA, Paris, France
[3] Childrens & Youth Hosp Auf Der Bult, Diabet Ctr Children & Adolescents, Hannover, Germany
[4] Univ Calif San Diego, San Diego, CA 92103 USA
[5] Kings Coll Hosp NHS Fdn Trust, London, England
[6] Kings Coll London, Sch Life Course Sci, Dept Diabet, London, England
[7] Univ Montpellier, Montpellier Univ Hosp, Dept Endocrinol Diabet & Nutr, Montpellier, France
[8] Univ Montpellier, Inst Funct Genom, Montpellier, France
[9] INSERM Clin Invest Ctr, Montpellier, France
[10] Int Diabet Ctr Pk Nicollet, Minneapolis, MN USA
来源：
DIABETES THERAPY | 2020年 / 11卷 / 07期
关键词：
D O I：
10.1007/s13300-020-00820-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In the original publication, the timing of baseline CGM assessment was incorrectly stated in the text in two instances; it is correct in Fig. 1.
引用
收藏
页码：1607 / 1608
页数：2
相关论文
共 50 条
  • [31] Comparison of Insulin Glargine 300 U/mL and Insulin Degludec 100 U/mL Around Spontaneous Exercise Sessions in Adults with Type 1 Diabetes: A Randomized Cross-Over Trial (ULTRAFLEXI-1 Study)
    Moser, Othmar
    Mueller, Alexander
    Aberer, Felix
    Aziz, Faisal
    Kojzar, Harald
    Sourij, Caren
    Obermayer, Anna
    Abbas, Farah
    Birnbaumer, Philipp
    Lenz, Jacqueline
    Mursic, Ines
    Sternad, Christoph
    Hoenger, Lukas
    Ziko, Haris
    Pferschy, Peter N.
    Tripolt, Norbert
    Sourij, Harald
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 (03) : 161 - 168
  • [32] Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial
    Haluzik, Martin
    Cheng, Alice
    Mueller-Wieland, Dirk
    Westerbacka, Jukka
    Bosnyak, Zsolt
    Lauand, Felipe
    Melas-Melt, Lydie
    Karalliedde, Janaka
    Rosenstock, Julio
    Bolli, Geremia B.
    DIABETES OBESITY & METABOLISM, 2020, 22 (08): : 1369 - 1377
  • [33] Similar glycaemic control and less or comparable hypoglycaemia with insulin glargine 300 U/ml vs degludec 100 U/ml in insulin naive type 2 diabetes: the BRIGHT randomised study
    Cheng, A.
    Rosenstock, J.
    Ritzel, R.
    Bosnyak, Z.
    Devisme, C.
    Stella, P.
    Cali, A. M. G.
    Wang, X.
    Frias, J.
    Roussel, R.
    Bolli, G. B.
    DIABETOLOGIA, 2018, 61 : S42 - S42
  • [34] Lower hypoglycemia rates with Glargine 300 U/mL vs. insulin Degludec 100 U/mL in insulin-naive adults with type 2 diabetes - The BRIGHT Randomized Study
    Bolli, Geremia
    Scherer, Thomas
    Cheng, Alice
    Bosnyak, Zsolt
    Boelle-Le Corfec, Emmanuelle
    Cali, Anna
    Wang, Xiangling
    Frias, Juan
    Roussel, Ronan
    Rosenstock, Julio
    WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 : 369 - 369
  • [35] Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections
    Bergenstal, RichardM.
    Bailey, Timothy S.
    Rodbard, David
    Ziemen, Monika
    Guo, Hailing
    Muehlen-Bartmer, Isabel
    Ahmann, Andrew J.
    DIABETES CARE, 2017, 40 (04) : 554 - 560
  • [36] INSULIN GLARGINE 300 U/ML VS 100 U/ML: GLUCOSE PROFILES OF MORNING VS EVENING INJECTIONS IN ADULTS WITH T1DM MEASURED WITH CONTINUOUS GLUCOSE MONITORING (CGM)
    Bergenstal, R.
    Bailey, T. S.
    Rodbard, D.
    Guo, H.
    Muehlen-Bartmer, I.
    Ahmann, A. J.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A17 - A18
  • [37] Comparison of the basal insulin analogues Gla-300 and IDeg 100 using continuous glucose monitoring in people with type 1 diabetes: the InRange randomised controlled trial
    Battelino, T.
    Danne, T.
    Edelman, S.
    Choudhary, P.
    Renard, E.
    Westerbacka, J.
    Mukherjee, B.
    Picard, P.
    Pilorget, V.
    Bergenstal, R.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S130 - S130
  • [38] New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)
    Terauchi, Y.
    Koyama, M.
    Cheng, X.
    Takahashi, Y.
    Riddle, M. C.
    Bolli, G. B.
    Hirose, T.
    DIABETES OBESITY & METABOLISM, 2016, 18 (04): : 366 - 374
  • [39] Comparative Effectiveness of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (iDeg-100) in Insulin-Nave Type 2 Diabetes Adults: RESTORE-2 Real-World Study
    Fadini, Gian Paolo
    Buzzetti, Raffaella
    Nicolucci, Antonio
    Rossi, Maria Chiara
    Larosa, Monica
    Cucinotta, Domenico
    DIABETES, 2021, 70
  • [40] Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study
    Abitbol, Alexander
    Brown, Ruth E.
    Jiandani, Dishay
    Sauriol, Luc
    Aronson, Ronnie
    CANADIAN JOURNAL OF DIABETES, 2019, 43 (07) : 504 - +
12345